Embedded Files
Sensible Biotechnologies, with NVIDIA's AI support, has cut the optimization time for its in vivo mRNA design platform from 15 days to just one.
Why it matters:
This breakthrough could revolutionize the scalability and safety of mRNA therapies, crucial for conditions like cancer and rare diseases.
The cell-based method produces purer mRNA products, potentially reducing immune responses and enhancing therapeutic efficacy.
Tech integration:
Sensible uses NVIDIA's BioNeMo framework and NIM microservices on the DGX Cloud platform, enabling over 11,000 simulation steps per second.
This setup accelerates the testing of multiple RNA candidates, reducing simulation times from hours to under an hour.
Innovative approach:
The closed-loop platform employs physics-based simulations and machine learning to model RNA folding in biological environments.
This enhances the stability and function of therapeutic candidates before manufacturing.
What they're saying:
"Producing therapeutic mRNA inside living cells requires solving intricate biological problems," said Krishna Motheramgari, principal computational scientist at Sensible.
"This integration brings us closer to programmable, high-performance RNA medicines," added CEO Miroslav Gasparek.
Looking ahead:
The novel approach lays the foundation for rationally designed mRNA therapeutics, paving the way for advanced treatments and precision medicine.
Page updated
Report abuse